CEGE: CEO Discusses Takeda Agreement for GVAX Immunotherapy in Prostate Cancer

By admin | April 2, 2008
Rating 3.00 out of 5
[?]

Submitted By Knobias ClipReport

Shares of Cell Genesys, Inc. (CEGE) surged in today’s session following the announcement of a global alliance with Takeda Pharmaceutical Company Limited for the development and commercialization of GVAX immunotherapy for prostate cancer.

More Here>

Comments